Physician profile
Heather Gros
NPI 1881167039
$4,299.17
in general payments reported to CMS, 2019-2025
26 companies · $525 in 2025
The $525 reported for 2025 was more than what 77% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,248 · 2022: $980 · 2023: $714 · 2024: $832 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $434.16 | 2021-2024 | Azure Xt Dr Mri Surescan, Selectsecure, Linq II |
| Kestra Medical Technology Services, INC. | $413.27 | 2022-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $402.80 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $384.44 | 2021-2025 | Camzyos, Eliquis, Empliciti |
| Merck Sharp & Dohme LLC | $372.71 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $326.74 | 2021-2024 | Xarelto |
| Amgen INC. | $313.45 | 2021-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $257.65 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $233.01 | 2021-2024 | |
| Esperion Therapeutics, INC. | $231.34 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $184.36 | 2021-2025 | Farxiga |
| Inspire Medical Systems, INC. | $121.92 | 2022 | |
| Pfizer INC. | $103.98 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.70 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.30 | 2021-2023 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $72.85 | 2021 | |
| Scpharmaceuticals INC. | $57.88 | 2023-2025 | |
| Boston Scientific Corporation | $51.75 | 2021-2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $35.60 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals International, Plc | $32.15 | 2024 | Arcalyst |
| Btg International INC. | $22.47 | 2021 | |
| Glaxosmithkline, LLC. | $22.33 | 2025 | Shingrix |
| Kiniksa Pharmaceuticals, LTD. | $19.07 | 2023 | Arcalyst |
| Astellas Pharma US INC | $18.16 | 2021 | |
| Novo Nordisk INC | $16.22 | 2023 | Rybelsus, Ozempic |
| Abbvie INC. | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Gros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.